Have a feature idea you'd love to see implemented? Let us know!

AKYA Akoya Biosciences Inc

Price (delayed)

$2.49

Market cap

$123.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$195.09M

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive ...

Highlights
Akoya Biosciences's EPS has increased by 34% YoY and by 4.1% from the previous quarter
Akoya Biosciences's net income has increased by 19% YoY and by 3.9% QoQ
The equity has dropped by 78% year-on-year and by 39% since the previous quarter
The company's quick ratio fell by 34% YoY and by 8% QoQ

Key stats

What are the main financial stats of AKYA
Market
Shares outstanding
49.56M
Market cap
$123.41M
Enterprise value
$195.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.04
Price to sales (P/S)
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.25
Earnings
Revenue
$86.82M
Gross profit
$50.11M
Net income
-$57.97M
EBIT
-$47.7M
EBITDA
-$39.79M
Free cash flow
-$48.71M
Per share
EPS
-$1.16
EPS diluted
-$1.16
Free cash flow per share
-$0.98
Book value per share
$0.28
Revenue per share
$1.75
TBVPS
$1.95
Balance sheet
Total assets
$129.97M
Total liabilities
$116.34M
Debt
$84.92M
Equity
$13.63M
Working capital
$48.87M
Liquidity
Debt to equity
6.23
Current ratio
2.75
Quick ratio
1.76
Net debt/EBITDA
-1.8
Margins
EBITDA margin
-45.8%
Gross margin
57.7%
Net margin
-66.8%
Operating margin
-58%
Efficiency
Return on assets
-38.1%
Return on equity
-189.5%
Return on invested capital
-34%
Return on capital employed
-46.8%
Return on sales
-54.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKYA stock price

How has the Akoya Biosciences stock price performed over time
Intraday
-2.35%
1 week
9.69%
1 month
15.28%
1 year
-47.13%
YTD
-48.98%
QTD
-8.46%

Financial performance

How have Akoya Biosciences's revenue and profit performed over time
Revenue
$86.82M
Gross profit
$50.11M
Operating income
-$50.34M
Net income
-$57.97M
Gross margin
57.7%
Net margin
-66.8%
The company's operating income rose by 22% YoY and by 4.1% QoQ
Akoya Biosciences's net income has increased by 19% YoY and by 3.9% QoQ
Akoya Biosciences's operating margin has increased by 18% YoY but it has decreased by 3% from the previous quarter
The net margin has grown by 14% YoY but it has contracted by 3.2% from the previous quarter

Growth

What is Akoya Biosciences's growth rate over time

Valuation

What is Akoya Biosciences stock price valuation
P/E
N/A
P/B
9.04
P/S
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.25
Akoya Biosciences's EPS has increased by 34% YoY and by 4.1% from the previous quarter
The equity has dropped by 78% year-on-year and by 39% since the previous quarter
AKYA's price to book (P/B) is 37% higher than its last 4 quarters average of 6.6
The price to sales (P/S) is 25% lower than the last 4 quarters average of 1.9
The revenue has decreased by 7% QoQ and by 5% YoY

Efficiency

How efficient is Akoya Biosciences business performance
The ROE has plunged by 56% YoY and by 34% from the previous quarter
The return on invested capital is up by 46% year-on-year and by 12% since the previous quarter
Akoya Biosciences's ROS has increased by 20% YoY
Akoya Biosciences's return on assets has increased by 7% YoY but it has decreased by 3.5% QoQ

Dividends

What is AKYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKYA.

Financial health

How did Akoya Biosciences financials performed over time
AKYA's total assets is 12% greater than its total liabilities
The company's quick ratio fell by 34% YoY and by 8% QoQ
AKYA's total assets is down by 27% year-on-year and by 10% since the previous quarter
The equity has dropped by 78% year-on-year and by 39% since the previous quarter
Akoya Biosciences's debt to equity has soared by 64% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.